Evaluation of the effect of plasmapheresis in the treatment of Covid 19
Phase 2
Recruiting
- Conditions
- Covid 19 induced acute respiratory distress syndrome.Covid 19 virus identifiedU07.1
- Registration Number
- IRCT20200405046958N2
- Lead Sponsor
- Mashhad University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 42
Inclusion Criteria
The patient must be definitive case of Covid-19 based on positive PCR test.
The patient must have clinical and paraclinical criteria for acute respiratory distress syndrome (ARDS)
The patient age must be over 15 years
There must be the informed consent of the patient or his/her legal guardian
Exclusion Criteria
The patient has unstable hemodynamics
The patient has a history of previous acute cardiac infarction in the last 3 months
The patient has a history of allergies to blood products
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Death. Timepoint: first 30 days of hospital admission. Method of measurement: examination of vital signs.
- Secondary Outcome Measures
Name Time Method Disease severity. Timepoint: 1st, 3rd and 7th day after ICU admission. Method of measurement: Use of SAPS3 and SOFA scoring systems.;ICU ward stay. Timepoint: Day 30 and 60 from hospital admission. Method of measurement: Patient visit.;Mechanical ventilation duration. Timepoint: All days of ICU admission. Method of measurement: Daily visit.;Changes in CRP and Ferritin inflammatory markers. Timepoint: Days 0, 3 and 7 after ICU admission. Method of measurement: Serum levels of CRP and ferritin tests.